Company news
Neuren Pharmaceuticals Limited (ASX:NEU) news
Neuren Pharmaceuticals Limited news releases on 6ix. Latest, Feb 29, 2024: Neuren reports profit of $157 million for 2023
Press releases — page 2
Neuren reports profit of $157 million for 2023
February 29, 2024
Appendix 4E and 2023 full year accounts
February 29, 2024
DAYBUE net sales US$87.1 million in Q4 2023
February 27, 2024
Comment on research report
February 16, 2024
Q4 2023 Appendix 4C Cash Flow Report
January 31, 2024
Q4 2023 quarterly activity report
January 31, 2024
Completion of enrolment in Neuren's Angelman P2 trial
December 19, 2023
Investor presentation, 18 December 2023
December 17, 2023
P2 trial shows significant improvements in Phelan-McDermid
December 17, 2023
Neuren completes enrolment in Pitt Hopkins Phase 2 trial
December 4, 2023
DAYBUE net sales US$66.9 million in Q3 2023
November 2, 2023
Q3 2023 quarterly activity and cash flow report
October 19, 2023
S&P DJI Announces September 2023 Quarterly Rebalance
September 1, 2023
Q2 2023 quarterly activity and cash flow report
July 30, 2023
Neuren receives US$100m for expanded DAYBUE agreement
July 27, 2023
Neuren and Acadia expand global partnership for trofinetide
July 13, 2023
Neuren completes enrolment in Phelan-McDermid Phase 2 trial
June 29, 2023
Neuren opens first site in US for Prader-Willi Phase 2 trial
June 28, 2023
Neuren receives US$40m milestone payment
June 7, 2023
Q1 2023 quarterly activity and cash flow report
April 27, 2023
DAYBUE (trofinetide) launched in US - Neuren earns US$40m
April 18, 2023
FDA approves Daybue - the first treatment for Rett syndrome
March 12, 2023
Neuren reports 2022 full-year results
February 23, 2023
Appendix 4E and 2022 full year accounts
February 23, 2023
Q4 2022 quarterly activity and cash flow report
January 30, 2023
Prader-Willi syndrome IND for NNZ-2591 approved by FDA
January 22, 2023
Neuren submits IND & first patients complete Phase 2 trials
December 22, 2022
Q3 2022 quarterly activity and cash flow report
October 26, 2022
Neuren receives US$10 million milestone payment
October 19, 2022
Rett Syndrome NDA accepted for Priority Review by FDA
September 12, 2022
S&P DJI Announces September 2022 Quarterly Rebalance
September 2, 2022
Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS
August 7, 2022
Quarterly Activities/Appendix 4C Cash Flow Report
July 29, 2022
Acadia submits Rett Syndrome New Drug Application to the FDA
July 19, 2022
Neuren commences Phase 2 trial of NNZ-2591 in Angelman
July 11, 2022
Neuren appoints Chief Medical Officer in United States
July 8, 2022
FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial
March 24, 2022
FDA approval for Phelan-McDermid IND and Phase 2 trial
March 22, 2022
Ethics approval for Angelman Phase 2 trial in Australia
March 10, 2022
S&P DJI Announces March 2022 Quarterly Rebalance
March 4, 2022
FDA approval for Angelman IND and Phase 2 trial
February 24, 2022
2021 Results - a transformational year for Neuren
February 23, 2022
Preliminary Final Report and 2021 Full Year Accounts
February 23, 2022
Neuren Pharmaceuticals : Notification regarding unquoted securities - NEU
February 3, 2022
Q4 2021 quarterly activity and cash flow report
January 30, 2022
Positive topline results from Phase 3 trial in Rett syndrome
December 6, 2021
Neuren presenting at Bell Potter Healthcare Conference
November 9, 2021
Q3 2021 quarterly activity and cash flow report
October 27, 2021
Neuren receives feedback on IND for Phelan-McDermid syndrome
October 21, 2021
US patent to 2034 granted for Neurens NNZ-2591 in autism
October 10, 2021